---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-343525"
form_type: "8-K"
ticker: "RARE"
cik: "0001515673"
company_name: "Ultragenyx Pharmaceutical Inc."
filed_at: "2026-08-11T12:30:17+00:00"
generated_at: "2026-08-11T12:35:34.216400+00:00"
event_type: "litigation"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Ultragenyx settles DOJOLVI patent litigation; Esjay generic entry set for 2033

## Summary
- Settlement with Esjay resolves ANDA patent suit over DOJOLVI (triheptanoin) in NJ district court.
- Esjay gets non-exclusive royalty-free license to market generic DOJOLVI starting Jan 1, 2033, or Jul 1, 2033 if pediatric exclusivity granted.
- Other DOJOLVI ANDA patent suits against other filers remain pending in same court.
- Settlement to be submitted to FTC and DOJ as required by law.

## SEC filing metadata
- accession: 0001193125-26-343525
- form_type: 8-K
- ticker: RARE
- cik: 0001515673
- company_name: Ultragenyx Pharmaceutical Inc.
- filed_at: 2026-08-11T12:30:17+00:00
- event_type: litigation
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1515673/000119312526343525/0001193125-26-343525-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1515673/000119312526343525/rare-20260807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-343525
- JSON: https://secwatch.observer/filing/0001193125-26-343525.json
- Plain text: https://secwatch.observer/filing/0001193125-26-343525.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.